Transfection Reagents and Equipment Global Market Report 2024

The transfection reagents and equipment market has grown rapidly in recent years. It will grow from $1.46 billion in 2023 to $1.62 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%. The expansion observed in the historical period can be credited to the increasing demand for biomedical research, advancements in pharmaceutical development, the upsurge in biotechnology applications, the presence of academic and research institutions, and progress in genetic engineering.

The transfection reagents and equipment market is expected to see rapid growth in the next few years. It will grow to $2.43 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The anticipated expansion in the forecast period can be ascribed to advancements in gene therapy, growing requirements for bioproduction, the emergence of cell-based therapies, research and development efforts in personalized medicine, and the fostering of global collaborations. Key trends expected during the forecast period encompass a concentration on primary cell transfection, a transition towards electroporation techniques, the incorporation of nanotechnology in transfection processes, a rising demand for animal-free transfection reagents, and the adoption of automation and high-throughput transfection systems.

The anticipated increase in the global number of cancer patients is poised to drive the growth of the transfection reagents and equipment market in the future. Cancer, characterized by abnormal and uncontrolled cell growth, prompts the widespread use of transfection reagents in cancer research. These reagents facilitate the introduction of foreign genetic material, such as plasmid DNA or RNA molecules, enabling researchers to delve into various aspects of cancer biology, including gene expression studies, gene silencing, drug screening, and target validation. As an illustration, in 2021, the American Cancer Society reported 1.8 million new cancer cases diagnosed in 2020. Consequently, the escalating worldwide prevalence of cancer contributes to the expansion of the transfection reagents and equipment market.

The upward trajectory in healthcare expenditures is expected to fuel the growth of the transfection reagents and equipment market in the foreseeable future. Healthcare expenditures encompass all costs associated with delivering health services, family planning activities, nutrition programs, and emergency assistance with a focus on health. The increase in healthcare spending translates to higher investments in research and development, thereby boosting the demand for transfection reagents and equipment as indispensable tools for advancing genetic research, gene therapy, and biopharmaceutical development. For instance, as of June 2023, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported a 2.7% increase in healthcare expenditure in the United States, totaling $4.3 trillion or $12,914 per person in 2021. This expenditure accounted for 18.3% of the nation's gross domestic product. Consequently, the surge in healthcare expenditures is a driving force behind the growth of the transfection reagents and equipment market.

A prominent trend gaining traction in the transfection reagents and equipment market is product innovation, with major companies strategically focusing on developing inventive products to maintain their market standing. An example of this is Polyplus-Transfection SA, a France-based biotechnology company, which, in September 2022, introduced the in vivo-jetRNA+ transfection reagent. This novel product utilizes a preformed liposome formulation for in vivo mRNA delivery, offering a highly efficient and scalable gene delivery system capable of delivering mRNA to diverse tissues and cell types. Notably safe and well-tolerated, the reagent eliminates the need for formulation stages, and its stable liposome size accommodates varying mRNA concentrations over time. Applications include prophylactic vaccinations, mRNA treatments (such as cancer therapy and rare diseases), and gene editing.

Major companies in the transfection reagents and equipment market are intensifying their efforts to introduce innovative product lines. Mirus Bio LLC, a US-based biotechnology company, exemplifies this approach with the launch of the TransIT-VirusGEN GMP product line in August 2022. This product line, designed for efficient and scalable transfection of viral vectors, supports GMP manufacturing processes in gene therapy applications. Specifically tailored for large-scale therapeutic production of adeno-associated virus (AAV) and lentivirus vectors, the TransIT-VirusGEN GMP Transfection Reagent serves as an ancillary material for various products, including cell, gene, and tissue-engineered products, meeting USP < 1043 standards. The primary goal is to aid biopharmaceutical manufacturers in addressing challenges related to effectively and cost-effectively producing AAV and LV vectors with the requisite quality and volume for commercial viability.

In March 2023, Sartorius AG, a Germany-based analytical laboratory instrument manufacturing company, acquired Polyplus-Transfection SA for $2.6 billion. This acquisition positions Sartorius AG strongly in the rapidly expanding cell and gene therapy markets, supporting business growth and meeting the escalating demand for cell and gene therapies. Polyplus-Transfection SA, a France-based biotechnology company, specializes in the development of transfection reagents and equipment.

Major companies operating in the transfection reagents and equipment market report are Thermo Fisher Scientific Inc., Promega Corporation, Qiagen N.V., Bio-Rad Laboratories Inc., Maxcyte Inc., Lonza Group Ltd., Merck KGaA, Mirus Bio LLC, OriGene Technologies Inc., PromoCell GmbH, PerkinElmer Inc., Agilent Technologies Inc., Altogen Biosystems, Applied Biological Materials Inc., Bex Co. Ltd., Sartorius AG, Takara Bio Inc., Tecan Trading AG, Polyplus-transfection SA, Sigma-Aldrich Corporation, Hoffmann-La Roche Ltd., Transfection Technologies Inc., Viromer, ABM Inc., Bio-Techne Corporation, Biotium Inc., Cell Applications Inc., chemicell GmbH, Clontech Laboratories Inc., Genlantis, Inovio Pharmaceuticals Inc., Biontex Laboratories GmbH, Boca Scientific Inc., Jena Bioscience GmbH.

North America was the largest region in the transfection reagents and equipment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transfection reagents and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the transfection reagents and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Within the realm of transfection reagents and equipment, the primary categories encompass instruments and reagents, along with kits. Transfection instruments are specialized laboratory tools designed to streamline the delivery of foreign nucleic acids, such as DNA or RNA, into cells during the transfection process. The range of molecules involved includes plasmid DNA, DNA oligonucleotides, small interfering RNA (siRNA), proteins, ribonucleoprotein complexes (RNPs), and others. Various organisms, including bacteria, mammalian cells, fungi, plants, and viruses, serve as recipients for these molecules. These products find application across diverse end-users, including biopharma, contract research organizations (CROs), contract manufacturing organizations (CMOs), contract development and manufacturing organizations (CDMOs), academia, hospitals, clinical labs, and others.

The transfection reagents and equipment market research report provides transfection reagents and equipment market statistics, including transfection reagents and equipment industry global market size, regional shares, competitors with a transfection reagents and equipment market share, detailed transfection reagents and equipment market segments, market trends, and opportunities, and any further data you may need to thrive in the transfection reagents and equipment industry. This transfection reagents and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The transfection reagents and equipment market consists of sales of lipid-based transfection reagents, cationic polymer-based transfection reagents, calcium phosphate-based transfection reagents, viral transduction tools, transfection control plasmids, transfection validation tools, and electroporation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.